Skip to content
Menu
Home
about AesMed
AesMed Story
AGF39
3rd Evolution in the History of Alopecia Treatment: AGF39 Cytokines Therapy for Alopecia
2025-04-22
The journey to effectively treating hair loss has seen significant advancements, with the ...
Read More
Latest Posts
AesMed to Exhibit at WCHR 2026 in Seoul and Introduce the 1111 Hair Care Day Campaign
AesMed Showcases Hair-Loss Treatment Innovations at KALDAT 2026 and KSHRS 2026
Beyond the Device: How SCALPORIN™ R1 Fits into AGF39 Protocols and the CytoMesopecia Concept
Inside SCALPORIN™ R1: AesMed’s Professional Electroporation Scalp Device for Precision Delivery
Why Delivery Matters in Scalp Care: Electroporation, Active Solutions, and the Logic Behind Professional Treatment
AesMed Successfully Concludes KIMES 2026 Participation
From Conference Posters to Credibility: How SGF57 Built Trust – Series Part 3
The Clinical Study Behind the Original SGF57 Formula – Series Part 2
SGF57: The Original Blueprint Behind AGF39 – Series Part 1
AGF39: Clinical Experience, Real-World Data, and Global Adoption- part 4
Search for:
